Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

Next Previous
Trial Profile

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Cervical cancer; Colorectal cancer; Duodenal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Salivary gland cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms KEYLYNK-007; MK-7339-007/KEYLYNK-007
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 30 Apr 2025 Results assessing HRD-related biomarkers and their association with biomarkers that are predictive of response to pembrolizumab presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 30 Apr 2025 Results (At data cutoff (May 16, 2024), n=332) assessing the effect of olaparib plus pembrolizumab in HRRm/HRD advanced tumors presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 17 Mar 2025 Planned End Date changed from 24 Jul 2025 to 23 Jul 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top